Compare Avanos Medical, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 5.39%
- The company has been able to generate a Return on Capital Employed (avg) of 5.39% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -0.37% over the last 5 years
3
Flat results in Jun 25
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 597 Million (Micro Cap)
9.00
NA
0.00%
0.05
7.62%
0.77
Revenue and Profits:
Net Sales:
175 Million
(Quarterly Results - Jun 2025)
Net Profit:
-77 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.03%
0%
11.03%
6 Months
8.09%
0%
8.09%
1 Year
-17.15%
0%
-17.15%
2 Years
-32.77%
0%
-32.77%
3 Years
-56.03%
0%
-56.03%
4 Years
-58.37%
0%
-58.37%
5 Years
-72.48%
0%
-72.48%
Avanos Medical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.37%
EBIT Growth (5y)
-0.32%
EBIT to Interest (avg)
7.55
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
0.60
Tax Ratio
3.77%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
5.39%
ROE (avg)
4.86%
Valuation key factors
Factor
Value
P/E Ratio
9
Industry P/E
Price to Book Value
0.69
EV to EBIT
11.40
EV to EBITDA
6.23
EV to Capital Employed
0.70
EV to Sales
0.87
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
6.11%
ROE (Latest)
7.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 65 Schemes (52.96%)
Foreign Institutions
Held by 90 Foreign Institutions (7.36%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
175.00
167.50
4.48%
Operating Profit (PBDIT) excl Other Income
17.30
16.90
2.37%
Interest
2.00
2.10
-4.76%
Exceptional Items
-81.50
1.40
-5,921.43%
Consolidate Net Profit
-76.80
6.60
-1,263.64%
Operating Profit Margin (Excl OI)
41.70%
43.60%
-0.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 4.48% vs -6.74% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -1,263.64% vs 101.66% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
687.80
673.30
2.15%
Operating Profit (PBDIT) excl Other Income
85.50
108.50
-21.20%
Interest
12.20
15.00
-18.67%
Exceptional Items
-440.10
-47.50
-826.53%
Consolidate Net Profit
-386.30
-9.90
-3,802.02%
Operating Profit Margin (Excl OI)
58.20%
96.50%
-3.83%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 2.15% vs -1.58% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -3,802.02% vs -146.05% in Dec 2023
About Avanos Medical, Inc. 
Avanos Medical, Inc.
Pharmaceuticals & Biotechnology
Avanos Medical, Inc., formerly Halyard Health, Inc., is a medical technology company. The Company provides a portfolio of product offerings focused on surgical and interventional pain management, respiratory and digestive health. Its products include post-operative pain management solutions, minimally invasive interventional or chronic pain therapies, closed airway suction systems and enteral feeding tubes. The company’s products are sold under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, QUIKBLOC, HOMEPUMP, CORTRAK and other brand names.
Company Coordinates 
Company Details
5405 Windward Parkway , ALPHARETTA GA : 30004
Registrar Details






